Cullinan Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, disclosing operational and financial information for the third quarter.

Key Highlights

  • Exchange and ticker: Common stock, par value $0.0001 per share, trades on the Nasdaq Global Select Market under the symbol CGEM.
  • Shares outstanding: As of November 4, 2026, the company reported 64,920,924 shares of common stock outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.
  • Collaboration noted: The filing references potential milestone payments the company may receive from Taiho Pharmaceutical Co., Ltd.

Cullinan Therapeutics: Clinical-Stage Biopharmaceutical Company Discloses Q3 2026 Status

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company headquartered at One Main Street, Suite 1350, Cambridge, MA 02142, submitted its quarterly report covering the period ended September 30, 2026. The filing carries Commission File Number 001-39856 and was submitted under the company's Delaware incorporation with EIN 81-3879991.

According to the filing, the company confirmed it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and has submitted all required Interactive Data Files electronically in accordance with Rule 405 of Regulation S-T. The company described its business activities as including research and development programs, preclinical studies, and clinical trials for its product candidates, with an ongoing collaboration arrangement with Taiho Pharmaceutical Co., Ltd. that may generate milestone payments.

The filing contains forward-looking statements, which the company notes are made pursuant to safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. The company stated that such forward-looking statements involve "known and unknown risks, uncertainties, and other factors" and that actual results may differ materially. Among the risks cited are the company's reliance on third parties to conduct clinical trials and manufacture drug substance, its ability to obtain regulatory approvals, and the potential effects of international trade policies and supply chain dynamics on its operations.

What Was Disclosed

Cullinan Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, reporting 64,920,924 shares outstanding as of November 4, 2026, its non-accelerated filer and smaller reporting company classifications, and noting a collaboration with Taiho Pharmaceutical Co., Ltd.